AL-2846

N/A

Report date: 2025/05/07 14:45:45
NME

Base Information

Drug NameAL-2846
Drug Alias NameAL-2846
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatocyte growth factor receptor inhibitors
TargetsHepatocyte growth factor receptor
Therapy Area/IndicationsBone metastasesMedullary thyroid cancer (MTC)Solid tumours +[18] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAdvenchen Laboratories Nanjing Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesJiangsu Chia Tai-Tianqing Pharmaceutical Co LtdNanjing Ed Cheng Ningxin Pharmaceutical R & D Co Ltd
Inactive CompaniesN/A
Active IndicationsMedullary thyroid cancer (MTC)Solid tumoursProstatic Neoplasms +[11] 
Inactive IndicationsBone metastasesColorectal NeoplasmsNeurofibromatosis 1 +[7] 

Other Information

ATC CodeN/A
Related LinksN/A